Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma Journal Article
| Authors: | Grobmyer, S. R.; Maki, R. G.; Demetri, G. D.; Mazumdar, M.; Riedel, E.; Brennan, M. F.; Singer, S. |
| Article Title: | Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma |
| Abstract: | Background: The purpose of this study was to retrospectively analyze the relationship between neo-adjuvant chemotherapy (NAC) and outcome in patients with high-grade extremity sarcomas. Patients and methods: Inclusion criteria were high-grade, deep, >5cm extremity soft tissue sarcomas. Patients diagnosed between 1990 and 2001 were treated with surgery only (n=282) or NAC containing doxorubicin/ifosfamide/mesna (AIM) (n=74). The stratified Cox proportional hazards model was used to test the effect of NAC on disease-specific survival and recurrence while adjusting for known prognostic factors. Results: NAC was associated with improved disease-specific survival for this cohort of patients (P=0.02). This overall improvement appears to be driven by the benefit of NAC on disease-specific survival for patient with tumors >10cm. The 3-year disease-specific survival for tumors >10cm was 0.62 (95% CI: 0.53-0.71) for patients not receiving NAC and 0.83 (95% CI: 0.72-0.95) for patients receiving NAC. Conclusion: NAC with AIM was associated with a significant improvement in disease-specific survival in patients with high-grade extremity soft tissue sarcomas >10cm. These data emphasize the need for further prospective clinical studies of neo-adjuvant or adjuvant chemotherapy for patients with large high-grade extremity sarcomas. © 2004 European Society for Medical Oncology. |
| Keywords: | adolescent; adult; cancer survival; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; survival analysis; retrospective studies; major clinical study; cancer recurrence; doxorubicin; cancer adjuvant therapy; cancer patient; chemotherapy, adjuvant; chemotherapy; cancer grading; prospective studies; cohort studies; antineoplastic combined chemotherapy protocols; proportional hazards models; cohort analysis; retrospective study; ifosfamide; time factors; sarcoma; survival time; limb tumor; soft tissue sarcoma; extremities; mesna; soft tissue neoplasms; nonbiological model; humans; human; priority journal; article; neo-adjuvant |
| Journal Title: | Annals of Oncology |
| Volume: | 15 |
| Issue: | 11 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2004-11-01 |
| Start Page: | 1667 |
| End Page: | 1672 |
| Language: | English |
| DOI: | 10.1093/annonc/mdh431 |
| PROVIDER: | scopus |
| PUBMED: | 15520069 |
| DOI/URL: | |
| Notes: | Ann. Oncol. -- Cited By (since 1996):93 -- Export Date: 16 June 2014 -- CODEN: ANONE -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work